OPTHEA LTD (UKJ) - Total Assets
Based on the latest financial reports, OPTHEA LTD (UKJ) holds total assets worth €145.77 Million EUR (≈ $170.42 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
OPTHEA LTD - Total Assets Trend (2022–2025)
This chart illustrates how OPTHEA LTD's total assets have evolved over time, based on quarterly financial data. Also see how much is OPTHEA LTD worth for the company's overall valuation and market capitalisation.
OPTHEA LTD - Asset Composition Analysis
Current Asset Composition (June 2025)
OPTHEA LTD's total assets of €145.77 Million consist of 100.0% current assets and 0.0% non-current assets. Review OPTHEA LTD (UKJ) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 85.3% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how OPTHEA LTD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of OPTHEA LTD for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OPTHEA LTD's current assets represent 100.0% of total assets in 2025, an increase from 99.8% in 2022.
- Cash Position: Cash and equivalents constituted 85.3% of total assets in 2025, up from 74.3% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
OPTHEA LTD Competitors by Total Assets
Key competitors of OPTHEA LTD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
OPTHEA LTD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.57 | 2.94 | - |
| Quick Ratio | 1.57 | 2.94 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | €52.38 Million | €124.14 Million | - |
OPTHEA LTD - Advanced Valuation Insights
This section examines the relationship between OPTHEA LTD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.92 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | -69.9% |
| Total Assets | €56.80 Million |
| Market Capitalization | $8.89 Million USD |
Valuation Analysis
Below Book Valuation: The market values OPTHEA LTD's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: OPTHEA LTD's assets decreased by 69.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for OPTHEA LTD (2022–2025)
The table below shows the annual total assets of OPTHEA LTD from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | €56.80 Million ≈ $66.40 Million |
-69.91% |
| 2024-06-30 | €188.79 Million ≈ $220.72 Million |
+91.39% |
| 2023-06-30 | €98.64 Million ≈ $115.32 Million |
+64.27% |
| 2022-06-30 | €60.05 Million ≈ $70.20 Million |
-- |
About OPTHEA LTD
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macula… Read more